Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In April 2025, according to an article published by the Heart Rhythm Society, a recent clinical study, TRANSFORM-AF, found that GLP-1 receptor agonists (GLP-1 RAs), typically used for diabetes, may reduce atrial fibrillation (AF)-related events in patients with both obesity and AF
"I tried everything," the Truth Hurts singer revealed on the Just Trish podcast on June 19
Over the past year, there has been an explosion in the popularity of GLP-1 receptor agonist drugs namely Ozempic and Wegovy , which are respectively used to treat diabetes and obesity
Examples include: Wellbutrin, an antidepressant that can be used off-label for weight loss and smoking cessation Metformin, which is FDA approved to treat Type 2 diabetes and is also often used off-label for polycystic ovarian syndrome (PCOS) Contrave, a combination of Wellbutrin and naltrexone, a drug developed for the treatment of substance disorders Qsymia, a combination of the prescription weight loss drug phentermine and the anti-epilepsy drug Topamax (topiramate), which aids in weight loss when combined with a proper diet and exercise It may also decrease binge eating
OROS Research believes researchers deserve access to meaningful quality data, which is why batch-specific Certificates of Analysis are made publicly accessible whenever available
US$ 27.77
US$ 26.84
US$ 22.54
US$ 24.62
US$ 25.68
US$ 24.82
US$ 28.73
US$ 26.16
US$ 26.72
